John Neis

Third Wave Technologies, Inc. developed DNA and RNA detection technology. It provided molecular solutions for clinical, research, and agricultural customers. The company was founded in February 1993 and was headquartered in Madison, WI.

Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI.

Mithridion, Inc. develops and manufactures biopharmaceutical products. Its drugs are used for the treatment of Alzheimer's's disease and schizophrenia. The company was founded on November 19, 2004 and is headquartered in Madison, WI.

Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI.

Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin.

NimbleGen Systems, Inc. Develops micro-arrays used in bio-technology. It also supplies microarray products and services. The company combines photo-deposition chemistry with digital light projection to shorten array fabrication from months to hours. NimbleGen System was founded in 1999 & is headquartered in Madison, WI.

TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.